
Patients are being harmed by compounded semaglutide, and dosing errors appear to be the culprit. That’s what the FDA said in a letter that the agency sent out at the end of July.
Version: 20241125
Patients are being harmed by compounded semaglutide, and dosing errors appear to be the culprit. That’s what the FDA said in a letter that the agency sent out at the end of July.
No comments yet. Be the first to say something!